Drugs / Sigirone
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05351762 | Jul 2022 → May 2024 | head and neck squamous cell carcinoma | Xijing Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sigirone | “oral administration of Sigirone on the 1st-14th day, 2/day;” NCT05351762 ↗ |
| Route | Oral | “oral administration of Sigirone” NCT05351762 ↗ |